XTNT

Xtant Medical Holdings Inc. (XTNT) | Rumor.io

Xtant Medical Holdings

XTNT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,587

Bullish sentiment (50-day avg)88%

Price to earnings ratio32

Market capitalization50.5M

Earnings per share-0.08

Dividend yield (TTM)—

Revenue (annual)133.9M

Net income (annual)5M

Social

What share of all stock conversation is about XTNT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 28

$XTNT is up 37.3% on a real headline, specifically in the surgical & medical instruments & apparatus sector, following a recent PR.
Xtant Medical Holdings is climbing steadily with solid overnight volume, showing strengthening momentum in the US overnight session.
The stock is experiencing a significant trading volume, with over 660K shares traded, and some investors are optimistic about a potential breakout above $0.50.

Generated by AI

Sentiment

Of the messages about XTNT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.16	87.66% +0.24
Bearish	—	—	0% -13.16	12.34% -0.24

Bullish· Jul 23

$XTNT is expected to release four new biologic products in 2021, potentially leading to meaningful revenue growth.
Xtant Medical Holdings, Inc. has undergone significant transformation through strategic and operational initiatives, positioning the company for future growth and strengthening its financial position.
$XTNT is considered undervalued and may experience a major bounce or surge in price, making it a potentially explosive investment opportunity.

Bearish· Jul 21

$XTNT is down 30% since it was identified as a pump, indicating a potential loss of investor confidence.
The company has significantly increased its outstanding shares, diluting the value of existing shares and potentially making it more difficult for the stock to appreciate in value.
Investors have reported taking significant losses on $XTNT, with some even calling it the "worst stock" they've ever had to hold onto.

Generated by AI

Topics

Of the messages about XTNT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	81.52%
Analysts	—	—	0%	6.16%
Controversies	—	—	0%	0.47%
Earnings	—	—	0%	2.37%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	9.48%

Earnings· Mar 9

$XTNT reported record fourth quarter revenue of $24.5 million, a 10% growth compared to the prior year period.
Analysts expect $XTNT to announce earnings of ($0.30) per share for the quarter, with the company missing EPS by 19% despite strong revenue growth.
The increase in SG&A expense from $15.1 million to $16.4 million is cited as a reason for the EPS miss, with some speculating that earnings may have been pre-announced, leading to a lack of a big spike during the announcement.

Announcements· May 11

Xtant Medical Holdings, Inc. (XTNT) filed a shelf registration statement for $150 million.
The company announced its first quarter 2021 financial results, with sales of $12.54 million missing estimates of $14.02 million.
Xtant Medical Holdings, Inc. filed SEC Form 10-Q and Form 8-K, providing financial statements and results of operations.

Technical Analysis· Feb 26

The stock has shown a strong trend reversal, with the 9/21/50 EMA cross and the 100 SMA above the 200 SMA, indicating a potential multi-day runner.
The stock is forming a cup and handle pattern, which could lead to a significant price increase if it breaks above the 4.7-4.8 level and then the 5 level.
The stock has a clear support level at 4.40ish and a potential wall at 5, with the author suggesting that traders should watch for the stock to settle at any level before making a decision.

Generated by AI

Community

Of the messages about XTNT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	5.88%	66.59%
Newcomers	—	—	94.12%	33.41%

Regulars· Jul 21

The price of XTNT is up 28.67% on 95,321 volume, trading at $1.84.
Historical data suggests that when XTNT rises by 29.6% during a trading day, it has traded lower by the same day's market close 78% of the time.
XTNT is trading at a high of $1.77 and $1.78 in pre-market, with gains of 24.65% and 25.35% respectively.

Newcomers· Aug 28

Many newcomers are buying XTNT, with some setting ambitious price targets, such as reaching $0.50.
Several users are discussing a potential short squeeze, citing the stock's 37.3% increase on a recent headline about surgical and medical instruments.
New investors are taking notice of XTNT's increasing volume, with some users commenting on its strengthening momentum and others tracking its live performance.

Generated by AI

News

Lucid Capital initiates Xtant Medical stock with buy rating

27d agoInvesting.com

Xtant Medical partners with BioHorizons for dental distribution

1mo agoInvesting.com

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

1mo agoMorningstar

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)

Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Xtant Medical at Canaccord Genuity: growth plan leans on biologics

1mo agoInvesting.com

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Moby summary of Xtant Medical Holdings, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Also Discussed

Investors talking about XTNT also mention

#	Name	Attention
1	Delcath Systems, Inc.DCTH	0%new
2	BLPH - Bellerophon Therapeutics, Inc.	——
3	NAVB - Navidea Biopharmaceuticals, Inc.	——
4	Moleculin Biotech, Inc.MBRX	0%0
5	Pulmatrix Inc.PULM	0%0
6	Opus Genetics Inc.OCUP	0%0
7	OPGN - OpGen, Inc.	——
8	Daré Bioscience, Inc.DARE	0%0
9	GMAN - Goldman Sachs Manufacturing Revolution ETF	——
10	Vericel CorporationVCEL	0%0

Xtant Medical Holdings Inc.

Healthcare
Medical Devices

Xtant Medical Holdings Inc. is a leading company in the medical device sector, specializing in the development and distribution of regenerative medicine products and surgical implants. The core purpose of the company is to improve patient outcomes through innovative solutions in orthopedic and neurological surgery. Xtant Medical’s product offerings include biologics and other advanced materials designed to support the healing and repair of tissue, primarily within the spine and broader orthopedics market. Their products are integral in the treatment of complex injuries and conditions, playing a crucial role in both surgical intervention and recovery processes. Based in the healthcare industry, Xtant Medical Holdings Inc. serves hospitals, surgical centers, and clinics, providing essential tools for managing patient care. In the financial market, Xtant's products and innovations position the company as a critical provider within the medical technology landscape, underlining its market presence and influence in advancing medical treatments.

Website

Location

664 Cruiser Lane

Belgrade, MT, 59714

United States

Social

What share of all stock conversation is about XTNT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 28

$XTNT is up 37.3% on a real headline, specifically in the surgical & medical instruments & apparatus sector, following a recent PR.
Xtant Medical Holdings is climbing steadily with solid overnight volume, showing strengthening momentum in the US overnight session.
The stock is experiencing a significant trading volume, with over 660K shares traded, and some investors are optimistic about a potential breakout above $0.50.

Generated by AI

Sentiment

Of the messages about XTNT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.16	87.66% +0.24
Bearish	—	—	0% -13.16	12.34% -0.24

Bullish· Jul 23

$XTNT is expected to release four new biologic products in 2021, potentially leading to meaningful revenue growth.
Xtant Medical Holdings, Inc. has undergone significant transformation through strategic and operational initiatives, positioning the company for future growth and strengthening its financial position.
$XTNT is considered undervalued and may experience a major bounce or surge in price, making it a potentially explosive investment opportunity.

Bearish· Jul 21

$XTNT is down 30% since it was identified as a pump, indicating a potential loss of investor confidence.
The company has significantly increased its outstanding shares, diluting the value of existing shares and potentially making it more difficult for the stock to appreciate in value.
Investors have reported taking significant losses on $XTNT, with some even calling it the "worst stock" they've ever had to hold onto.

Generated by AI

Topics

Of the messages about XTNT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	81.52%
Analysts	—	—	0%	6.16%
Controversies	—	—	0%	0.47%
Earnings	—	—	0%	2.37%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	9.48%

Earnings· Mar 9

$XTNT reported record fourth quarter revenue of $24.5 million, a 10% growth compared to the prior year period.
Analysts expect $XTNT to announce earnings of ($0.30) per share for the quarter, with the company missing EPS by 19% despite strong revenue growth.
The increase in SG&A expense from $15.1 million to $16.4 million is cited as a reason for the EPS miss, with some speculating that earnings may have been pre-announced, leading to a lack of a big spike during the announcement.

Announcements· May 11

Xtant Medical Holdings, Inc. (XTNT) filed a shelf registration statement for $150 million.
The company announced its first quarter 2021 financial results, with sales of $12.54 million missing estimates of $14.02 million.
Xtant Medical Holdings, Inc. filed SEC Form 10-Q and Form 8-K, providing financial statements and results of operations.

Technical Analysis· Feb 26

The stock has shown a strong trend reversal, with the 9/21/50 EMA cross and the 100 SMA above the 200 SMA, indicating a potential multi-day runner.
The stock is forming a cup and handle pattern, which could lead to a significant price increase if it breaks above the 4.7-4.8 level and then the 5 level.
The stock has a clear support level at 4.40ish and a potential wall at 5, with the author suggesting that traders should watch for the stock to settle at any level before making a decision.

Generated by AI

Community

Of the messages about XTNT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	5.88%	66.59%
Newcomers	—	—	94.12%	33.41%

Regulars· Jul 21

The price of XTNT is up 28.67% on 95,321 volume, trading at $1.84.
Historical data suggests that when XTNT rises by 29.6% during a trading day, it has traded lower by the same day's market close 78% of the time.
XTNT is trading at a high of $1.77 and $1.78 in pre-market, with gains of 24.65% and 25.35% respectively.

Newcomers· Aug 28

Many newcomers are buying XTNT, with some setting ambitious price targets, such as reaching $0.50.
Several users are discussing a potential short squeeze, citing the stock's 37.3% increase on a recent headline about surgical and medical instruments.
New investors are taking notice of XTNT's increasing volume, with some users commenting on its strengthening momentum and others tracking its live performance.

Generated by AI

Xtant Medical Holdings

Social

Aug 28

Bullish· Jul 23

Bearish· Jul 21

Earnings· Mar 9

Announcements· May 11

Technical Analysis· Feb 26

Regulars· Jul 21

Newcomers· Aug 28

Lucid Capital initiates Xtant Medical stock with buy rating

Xtant Medical partners with BioHorizons for dental distribution

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)

Xtant Medical at Canaccord Genuity: growth plan leans on biologics

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Also Discussed

Xtant Medical Holdings Inc.

Company Information

Location

Lucid Capital initiates Xtant Medical stock with buy rating

Xtant Medical partners with BioHorizons for dental distribution

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)

Xtant Medical at Canaccord Genuity: growth plan leans on biologics

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Also Discussed

Social

Aug 28

Bullish· Jul 23

Bearish· Jul 21

Earnings· Mar 9

Announcements· May 11

Technical Analysis· Feb 26

Regulars· Jul 21

Newcomers· Aug 28